Cargando…
P1609: CAPLACIZUMAB THERAPY IN OLDER PATIENTS (≥60 YEARS) WITH IMMUNE THROMBOTIC THROMBOCYTOPENIC PURPURA (ITTP). RESULTS OF THE SPANISH TTP REGISTRY
Autores principales: | Rubia, Javier DE LA, Gómez-Seguí, Inés, Cid, Joan, Valcárcel, David, Goterris, Rosa, Zarzoso, Miguel Fernández, Mingot-Castellano, María Eva, Izquierdo, Cristina Pascual, Hernández, Ana Oliva, Nieto, Jorge Martínez, Idrovo, Laura F. Ávila, Coronel, María Liz Paciello, Hernández, Luis M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429946/ http://dx.doi.org/10.1097/01.HS9.0000973312.61163.bd |
Ejemplares similares
-
Caplacizumab as frontline therapy in addition to standard treatment in iTTP
por: Cid, Joan, et al.
Publicado: (2022) -
Management of acquired, immune thrombocytopenic purpura
(iTTP): beyond the acute phase
por: Westwood, John Paul, et al.
Publicado: (2022) -
Real-world effectiveness of caplacizumab vs the standard of care in immune thrombotic thrombocytopenic purpura
por: Izquierdo, Cristina Pascual, et al.
Publicado: (2022) -
Outcomes of Immune Thrombotic Thrombocytopenic Purpura (iTTP) With Upfront Cyclophosphamide vs. Rituximab
por: Abou-Ismail, Mouhamed Yazan, et al.
Publicado: (2020) -
P1608: REAL-WORLD INSIGHTS ON THE MANAGEMENT OF IMMUNE-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA (ITTP) WITH CAPLACIZUMAB IN BELGIUM
por: Dierickx, Daan, et al.
Publicado: (2023)